Baptist Memorial Health Care/Mid South NCORP Minority Underserved Consortium

浸信会纪念医疗保健/中南少数民族服务不足NCORP是浸信会纪念的一部分 医疗保健公司（BMHCC），一个非营利性的基于信仰的医疗保健系统，拥有22家医院，21 门诊肿瘤诊所，8个放射设施和19个门诊输液中心，为 每年约有8000名新癌症患者。BMHCC的服务区域覆盖111个县，430万 人这是三角洲地区管理局252个县和教区的44%， 被认为是美国最贫困的人口。BMHCC在这个种族中提供了25%的癌症治疗， 社会经济和文化多样的地区，其中有一些最高数量的癌症和 美国最脆弱的公共卫生基础设施。在我们的NCORP之前，这些患者无法获得临床 审判自2014年8月我们的NCORP开始以来的4年中，每年有90多名患者 2017/18年入组试验，包括168例患者; 39%的入组患者是少数民族，17%是少数民族。 居住在农村地区，13%没有保险，21%有医疗补助。我们的NCORP成员服务于多个 NCORP工作组和NCI指导委员会，包括癌症预防指导委员会。我们 利用我们独特的专业知识，在乳腺，胸部， 胃肠道和血液肿瘤学发展特定疾病研究小组，将我们的 NCORP的研究与我们的临床肿瘤护理计划密切相关。这一战略加快了我们在以下方面的进展： 在过去的两年里。我们在全系统范围内实施的电子健康记录系统EPIC 增强了我们的研究能力，特别是在癌症护理提供研究方面。在新的融资周期中，我们 我建议在整个BMHCC范围内扩大我们的NCORP研究基础设施，特别强调 增加密西西比州的病人招募。使用实施和团队科学 原则和数据驱动的方法，我们的总体目标是增加BMHCC肿瘤学的比例 参与临床试验的患者从2018年的<3%增加到2025年的10%。每年新增近8000个 癌症病例，这将大大超过NCORP的最低要求，对我们的利益 患者、社区和医疗保健系统，因为我们相信“最好的治疗方法是临床试验”。 我们的具体目标是增加：1。到2025年，通过扩展到我们所有的 密西西比机构; 2.）肿瘤学相关提供者的比例累积患者至>90%; 3.）临床试验 泌尿生殖和妇科肿瘤学活动; 4.）NCORP试验的平均年患者入组人数 90到250。实现我们的目标将有助于实现NCI的使命，即改善美国这一关键人口的健康状况。 通过缩小公认的一个重大健康差距， 少数民族和农村人口在密西西比三角洲地区的高质量的肿瘤治疗。

The Baptist Memorial Health Care/Mid-South Minority Underserved NCORP is part of Baptist Memorial Healthcare Corporation (BMHCC), a non-for-profit faith-based healthcare system with 22 hospitals, 21 outpatient oncology clinics, 8 radiation facilities, and 19 outpatient infusion centers, providing care for approximately 8000 new cancer patients each year. BMHCC’s service area covers 111 counties, 4.3 million people. This is 44% of the 252 counties and parishes in the Delta Regional Authority, congressionally acknowledged as the most indigent population in the US. BMHCC provides 25% of cancer care in this racially, socioeconomically and culturally diverse region, which has some of the highest volumes of cancer and the most fragile public health infrastructure in the US. Before our NCORP, these patients had no access to clinical trials. In the 4 years since our NCORP began in August 2014, more than 90 patients per year have been enrolled into trials, including 168 patients in 2017/18; 39% of our enrolled patients are racial minorities, 17% reside in rural areas, 13% are uninsured, 21% have Medicaid. Members of our NCORP serve on multiple NCORP taskforces and NCI Steering Committees, including the Cancer Prevention Steering Committee. We have used our unique expertise in establishing Multidisciplinary Care Delivery programs in Breast, Thoracic, Gastrointestinal and Hematologic Oncology to develop Disease-Specific Research Groups that link our NCORP research closely to our clinical oncology care programs. This strategy has accelerated our progress in the past 2 years. Our system-wide implementation of the Electronic Health Record system, EPIC, has enhanced our research ability, especially in Cancer Care Delivery Research. For the new funding cycle, we propose to expand our NCORP research infrastructure across the full extent of BMHCC, with special emphasis on increasing patient recruitment across the state of Mississippi. Using Implementation and Team Science principles and a data-driven approach, our overarching goal is to increase the proportion of BMHCC oncology patients who participate in clinical trials from <3% in 2018 to 10% by 2025. With almost 8000 annual new cancer cases, this would significantly exceed the minimum requirements of the NCORP, to the benefit of our patients, communities and healthcare system, because we believe that ‘the best treatment is a clinical trial.’ Our specific aims are to increase the: 1.) number of active sites from 5 to 16 by 2025, by expanding to all our Mississippi institutions; 2.) proportion of oncology-related providers accruing patients to >90%; 3.) clinical trials activity in urogenital and gynecologic oncology; 4.) average annual patient-enrollment into NCORP trials from 90 to >250. Achieving our goal will help achieve the NCI’s mission of improving the health of this key US population demographic by narrowing a major recognized health disparity: poor access of the large indigent, racial minority and rural populations within the Mississippi Delta region to high quality oncologic care.